Regulatory Filings • May 9, 2016
Regulatory Filings
Open in ViewerOpens in native device viewer
Press release
ISSOIRE, France, May 9 th, 2016 – BIOCORP (FR0012788065 – ALCOR / PEA‐PME eligible), a French company specializing in the development and manufacturing of innovative medical and drug delivery devices, announced today that it has won the European Product Line Strategy Leadership award granted by prestigious consulting firm Frost & Sullivan.
This product leadership award recognizes European companies that have demonstrated an outstanding ability to develop innovative products in a given field. Analysts and consultants from Frost & Sullivan chose the award winner after carrying out a study to identify the best strategies in Europe — particularly for enhancing the customer experience.
BIOCORP stood out from other companies on several complementary criteria highlighting its innovations in the development of medical devices for the pharmaceutical industry and consolidating its position as a pioneer in the field of connected devices: Breadth, Scalability, Technology Leverage, Features, Supply Chain Reliability, Price/Performance Value and Brand Equity.
Click here to consult the Best Practice Research: http://bit.ly/1rydpRI
Frost & Sullivan underlines the high potential of various technologies developed by BIOCORP, which has addressed several global healthcare delivery concerns, finding markets enthusiastically waiting for its solutions. BIOCORP has accurately amalgamated novel and emerging technologies to dramatically increase the access to new product developments by combining the latest innovations in digital transformation with advanced therapeutics' delivery and administration systems. BIOCORP has made the difference by providing a more automated, less-invasive, more personalized, and precise therapeutics administration technology, along with more comfortable and easier-to-use devices for both patients and clinicians1 .
"We are honored to receive this award from Frost & Sullivan. It is highlighting the potential of our innovating technology, which represents a genuine competitive asset and enables us to come up with unique and high-value solutions for the pharmaceutical industry, as well as our strong growth potential on a market eager for new solutions. It is a fair acknowledgment of our team members' hard work", said Jacques Gardette, BIOCORP's CEO.
1 Frost & Sulllivan : Product Line Strategy Leadership Award, Digital Health Solutions and Smart Drug Delivery Systems – Europe http://bit.ly/1rydpRI
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages almost 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
Founded in 2004 in Issoire (near Clermont-Ferrand), France, Biocorp is a French company specializing in the development and manufacturing of medical devices and innovative drug delivery systems. It is listed as 'Innovative Company' by the French public investment bank Bpifrance. With over twenty years of experience and more than 30 manufactured products, Biocorp is a key player in the industry, providing drug delivery solutions that meet the evolving needs of patients. Today, Biocorp continues to innovate in the area of medical plastics, its core business, and to market traditional devices (alternative to aluminum capsules, syringe and vial administration systems) that have been an important source of recurring income. Its solid expertise and capacity to innovate have allowed the company to develop new Internetconnected products, including: the DataPen, a reusable smart injection pen that automatically transmits data to a mobile app, helping patients to manage their treatment; and treatment management add-ons, which adapt to existing delivery devices and are compatible with most injection pens in the market. The company has a team of 43 employees. Biocorp is listed on Alternext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit: www.biocorp.fr Follow us on Twitter @BIOCORPSystems
Biocorp Jacques Gardette CEO [email protected]
Press relations ALIZE RP Caroline Carmagnol & Wendy Rigal 01 44 64 36 66 - 06 48 82 18 94 [email protected]
Eric Dessertenne Head of Business Development
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.